Author

Kai Schlepckow

German Center for Neurodegenerative DiseasesORCID 0000-0002-1119-2293Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:mouse· 3 Approach:statistical model· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1

Frequent Co-Authors

Christian HaassiD· 4 shared Stefan F. LichtenthaleriD· 3 shared Stephan A. MülleriD· 3 shared Astrid FeiteniD· 2 shared Bettina Brunner· 2 shared Brigitte NuscheriD· 2 shared Joseph W. LewcockiD· 2 shared Kathryn M. MonroeiD· 2 shared

Activity by Year

2020-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersNeuroscience

Christian HaassORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

NeuroscienceNature CommunicationsPeer-reviewedJan 24, 2026

TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism

Astrid Feiten, Kilian Dahm, Kai Schlepckow…·Christian Haass

This study investigates how TREM2 expression levels affect microglial function, metabolism, and response to TREM2 agonists in a mouse model of Alzheimer's disease.

39 citationstop 1%

mousebulk RNA-seq

𝕏 PostBluesky

NeurosciencebioRxivPreprintApr 10, 2025

Anti-Aβ immunotherapy-mediated amyloid clearance attenuates microglial activation without inducing exhaustion at residual plaques

Lis de Weerd, Selina Hummel, Stephan A. Müller…·Christian Haass

This study shows that long-term anti-Aβ treatment reduces amyloid plaques and microglial activation but leaves residual plaques with persistent immune activity.

DOI 10.1101/2025.04.10.645950

mouseproteomics

𝕏 PostBluesky

BiochemistryLife Science AlliancePeer-reviewedMar 13, 2025

The late onset Alzheimer's disease risk factor iRhom2/RHBDF2 is a modifier of microglial TREM2 proteolysis

Georg Jocher, Stephan A. Müller, Hung‐En Hsia…·Stefan F. Lichtenthaler

This study identifies iRhom2 as a modifier of ADAM17-mediated TREM2 proteolysis in microglia, linking it to Alzheimer's disease risk.

6 citations

mouseproteomics

𝕏 PostBluesky

NeuroscienceThe EMBO JournalPeer-reviewedAug 24, 2020

Intramembrane cleavage of TREM2 is determined by its intrinsic structural dynamics

Andrea Steiner, Kai Schlepckow, Bettina Brunner…·Franz Hagn

The paper investigates how structural dynamics of TREM2's transmembrane helix influence its intramembrane cleavage by gamma-secretase, linking flexibility to cleavage site specificity.

33 citations

humanprotein structure

𝕏 PostBluesky